Literature DB >> 26959208

Pregnancy-Associated Hypertension in Glucose-Intolerant Pregnancy and Subsequent Metabolic Syndrome.

Madeline Murguia Rice1, Mark B Landon, Michael W Varner, Brian M Casey, Uma M Reddy, Ronald J Wapner, Dwight J Rouse, Joseph R Biggio, John M Thorp, Edward K Chien, George Saade, Alan M Peaceman, Sean C Blackwell, J Peter VanDorsten.   

Abstract

OBJECTIVE: To evaluate whether pregnancy-associated hypertension (preeclampsia or gestational hypertension) among women with varying degrees of glucose intolerance during pregnancy is associated with maternal metabolic syndrome 5-10 years later.
METHODS: This was an observational cohort study of women previously enrolled in a treatment trial of mild gestational diabetes mellitus or an observational study of lesser degrees of glucose intolerance evaluated 5-10 years after their index pregnancy. At follow-up, women underwent anthropometric and blood pressure measurements and analysis of fasting glucose and serum lipids.
RESULTS: A total of 825 women (47% of eligible women from the original study) were included in this analysis and evaluated at a median 7 years after their index pregnancy at a median age of 35 years. Overall, 239 (29%) had subsequent metabolic syndrome. The frequency of metabolic syndrome and its components was highest in the women who had pregnancy-associated hypertension and delivered preterm. After adjusting for confounding factors, pregnancy-associated hypertension in women who delivered preterm was associated with subsequent hypertension (130/85 mm Hg or greater; relative risk 3.06, 95% confidence interval [CI] 1.95-4.80, P<.001), high triglycerides (150 mg/dL or greater; relative risk 1.82, 95% CI 1.06-3.14, P=.03), and metabolic syndrome (per the American Heart Association and National Heart Lung and Blood Institute Scientific Statement; relative risk 1.78, 95% CI 1.14-2.78, P=.01) compared with women who remained normotensive throughout their index pregnancy and were delivered at term.
CONCLUSION: Women with varying degrees of glucose intolerance who experienced pregnancy-associated hypertension and then delivered preterm had a higher frequency of subsequent hypertension, high triglycerides, and metabolic syndrome 5-10 years later.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26959208      PMCID: PMC4805433          DOI: 10.1097/AOG.0000000000001353

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  Helicobacter pylori infection increases the risk of metabolic syndrome in pregnancy: a cohort study.

Authors:  Beilei Xia; Wenyuan Wang; Yufeng Lu; Chen Chen
Journal:  Ann Transl Med       Date:  2020-07

Review 2.  What we have learned about treating mild gestational diabetes mellitus.

Authors:  Madeline Murguia Rice; Mark B Landon
Journal:  Semin Perinatol       Date:  2016-04-25       Impact factor: 3.300

3.  Ceramide-induced BOK promotes mitochondrial fission in preeclampsia.

Authors:  Jonathan Ausman; Joelcio Abbade; Leonardo Ermini; Abby Farrell; Andrea Tagliaferro; Martin Post; Isabella Caniggia
Journal:  Cell Death Dis       Date:  2018-02-20       Impact factor: 8.469

4.  Comparison of Machine Learning Methods and Conventional Logistic Regressions for Predicting Gestational Diabetes Using Routine Clinical Data: A Retrospective Cohort Study.

Authors:  Yunzhen Ye; Yu Xiong; Qiongjie Zhou; Jiangnan Wu; Xiaotian Li; Xirong Xiao
Journal:  J Diabetes Res       Date:  2020-06-12       Impact factor: 4.011

5.  A Meta-Analysis of the Differences in Serum Lipid Levels between Pregnant Women with Hypertensive Disorder Complicating Pregnancy and Nonhypertensive Disorder Complicating Pregnancy.

Authors:  Yong Zhang; Yonghong Pei; Na Li
Journal:  Biomed Res Int       Date:  2022-10-03       Impact factor: 3.246

6.  Magnesium Sulfate in combination with Nifedipine in the treatment of Pregnancy-Induced Hypertension.

Authors:  Cuiping Xiang; Xuegui Zhou; Xiaoxia Zheng
Journal:  Pak J Med Sci       Date:  2020 Jan-Feb       Impact factor: 1.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.